Soluble PDGFRβ (sPDGFRβ) is released into the bloodstream upon pericyte damage, serving as a peripheral indicator of blood-brain barrier (BBB) pericyte coverage loss. Elevated plasma sPDGFRβ correlates with BBB leakage and cognitive decline trajectories. The mechanism involves ADAM10/ADAM17-mediated ectodomain shedding of PDGFRβ from damaged pericytes. This hypothesis has the strongest evidence base with human validation in Alzheimer's disease (AD) and vascular dementia cohorts. Specificity concerns regarding peripheral PDGFRβ+ cell sources (vascular smooth muscle cells, hepatic stellate cells) are addressable through cell-type-specific validation studies and parallel peripheral biomarker controls.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["PDGFRbeta Pericyte Receptor"]
B["PDGF-BB Ligand Signaling"]
C["Pericyte Detachment"]
D["BBB Compromise"]
E["Neurovascular Uncoupling"]
F["Neuroinflammation Microglial Activation"]
G["Cognitive Impairment"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
8 citations8 with PMIDValidation: 0%4 supporting / 4 opposing
✓For(4)
No supporting evidence
No opposing evidence
(4)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
6
2
MECH 6CLIN 2GENE 0EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
microRNA-320 dysregulation in AD plasma and brain …
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-26 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Mechanistic Hypotheses: BBB Permeability Biomarkers for Neurodegeneration
Hypothesis 1: Soluble PDGFRβ as a Peripheral Pericyte Degeneration Marker
Title: Circulating Soluble PDGFRβ Reflects Pericyte Loss and Precedes Cognitive Decline in Neurodegeneration
Description: Pericyte degeneration is among the earliest events in Alzheimer's disease (AD) and vascular dementia, preceding amyloid deposition and cognitive symptoms. Damaged pericytes release the ectodomain of platelet-derived growth factor receptor β (sPDGFRβ) into the bloodstream, making it a peripheral indicator o
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Critical Evaluation: BBB Permeability Biomarkers for Neurodegeneration
I will systematically evaluate each hypothesis for mechanistic plausibility, specificity, technical feasibility, and potential confounds. Where applicable, I will identify issues that span multiple hypotheses.
Hypothesis 1: Soluble PDGFRβ (Original: 0.82)
Specific Weaknesses
Non-CNS sources of sPDGFRβ: PDGFRβ is expressed on pericytes, vascular smooth muscle cells (VSMCs), cardiac fibroblasts, hepatic stellate cells, and renal mesangial cells. Systemic inflammatory conditions (atherosclerosis, pul
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Biomarker Utility: HIGH — sPDGFRβ functions as a pharmacodynamic/response biomarker rather than a direct therapeutic target. The underlying PDGFRβ signaling axis, however, represents a legitimate therapeutic target.
Therapeutic Approaches: | Strategy | Agent Class | De
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{"ranked_hypotheses": [{"title": "Circulating Soluble PDGFRβ Reflects Pericyte Loss and Precedes Cognitive Decline in Neurodegeneration", "description": "Soluble PDGFRβ (sPDGFRβ) is released into the bloodstream upon pericyte damage, serving as a peripheral indicator of blood-brain barrier (BBB) pericyte coverage loss. Elevated plasma sPDGFRβ correlates with BBB leakage and cognitive decline trajectories. The mechanism involves ADAM10/ADAM17-mediated ectodomain shedding of PDGFRβ from damaged pericytes. This hypothesis has the strongest evidence base with human validation in Alzheimer's dise
IF human cohorts with mild cognitive impairment or early Alzheimer's disease are stratified by presence/absence of peripheral PDGFRβ+ cell pathology (hepatic fibrosis stage ≥F2, or carotid intima-media thickness >1.0mm), THEN elevated baseline plasma sPDGFRβ (per SD increase) will remain independently associated with cognitive decline over 24 months (adjusted β >0.15 SD change per year on ADAS-Cog13), after adjustment for peripheral sources, age, APOE4 status, and baseline cognition.
pendingconf: 0.82
Expected outcome: Hazard ratio >1.8 for progression to dementia over 24 months in the high sPDGFRβ tertile vs. low tertile, independent of peripheral organ involvement.
Falsified by: The sPDGFRβ-cognition association becomes non-significant (p>0.05) after adjustment for peripheral PDGFRβ+ cell damage markers (serum hyaluronic acid for hepatic stellate cells, pulse wave velocity for vascular smooth muscle), indicating peripheral sources confound the signal.
Method: Prospective cohort study (n=600) with plasma sPDGFRβ measurements at baseline and 12 months, neurocognitive testing at 0/6/12/18/24 months, abdominal MRI for liver fibrosis, carotid ultrasound, stratified analysis by peripheral burden score.
IF pericytes are selectively ablated via genetic or pharmacological targeting in a mouse model of neurodegeneration (APP/PS1 or 5xFAD cross with PDGFRβ-Cre:DTR system), THEN plasma sPDGFRβ levels will increase by >50% within 14 days and will temporally precede detectable cognitive deficits by at least 7 days, as measured by Morris water maze performance decline.
pendingconf: 0.78
Expected outcome: Plasma sPDGFRβ elevation to >150% of baseline by day 14, followed by >20% increase in escape latency by day 21 in pericyte-ablated vs. control mice.
Falsified by: No significant increase in plasma sPDGFRβ despite confirmed pericyte loss (verified by NG2 immunostaining) or sPDGFRβ elevation occurring only after cognitive deficits are already established.
Method: Double-transgenic mouse model with pericyte-specific diphtheria toxin receptor expression, serial plasma sPDGFRβ ELISA measurements (R&D Systems QUANTI海 kits), longitudinal behavioral phenotyping.